About Illumina, Inc.
Illumina, Inc. (ILMN) is a Healthcare company in the Laboratory Analytical Instruments industry with a market capitalisation of $39.1B. The stock trades at 47.65x trailing earnings.
- Sector
- Healthcare
- Industry
- Laboratory Analytical Instruments
- Market cap
- $39.1B
- P/E ratio
- 47.65
- EPS (TTM)
- $5.45
- Revenue (TTM)
- $4.3B
- Free cash flow
- $931M
- Profit margin
- 19.6%
- Shares outstanding
- 151M
Financial health: Strong8.6/10
6 strengths, 1 concern. Weakest points: revenue growth.
- Current ratio: 2.08 (Strong, benchmark > 1.5) — Short-term assets cover 2.08x short-term liabilities, against Graham's 1.5x floor. It has improved over the last 4 years.
- Return on equity: 31.2% (Strong, benchmark > 15%) — Earns 31.2% on shareholder equity, comfortably past the > 15% mark.
- Gross margin: 66.1% (Strong, benchmark > 40%) — Keeps 66.1% of revenue after the direct cost of sales, comfortably past the > 40% mark.
- Net margin: 19.6% (Strong, benchmark > 10%) — Turns 19.6% of revenue into profit, comfortably past the > 10% mark.
- Free cash flow: $931.0M (Strong, benchmark positive) — Generated $931.0M of free cash flow after capital spending. It has improved over the last 4 years.
- Revenue growth: -0.7% (Concern, benchmark > 10%) — Revenue changed -0.7% year on year, well short of the > 10% mark.
- Earnings growth: 169.5% (Strong, benchmark > 10%) — Earnings changed 169.5% year on year, comfortably past the > 10% mark.